EUVIMEDEUVIMED entdecken
Crossref

Cytidinyl/Cationic Lipid Encapsulating Insulin-Like Growth Factor 1 Receptor siRNA for Hepatocellular Carcinoma Therapy

Yang Pu, Quanxin Wang, Yufei Pan iD, Xixian Wang, Zhu Guan, Yuejie Zhu, Zhenjun Yang iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c01318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Yang Pu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Receptor, IGF Type 1, RNA, Small Interfering, Liver Neoplasms. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, Beijing Daxing Biomedical Industry Base.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is the most prevalent form of invasive liver cancer, representing over 90% of all liver cancer cases. Currently, there is a lack of targeted therapy for HCC. Insulin-like growth factor 1 receptor (IGF1R) is abnormally expressed in HCC, leading to the malignant proliferation and contributing to the antiapoptosis mechanisms in tumor cells. In this study, small interfering RNAs targeting IGF1R mRNA (siIGF1Rs) have been designed. Additionally, a full 2'-F/2'-OMe modification with partial phosphorothioation was applied to improve the biological properties of these siIGF1Rs. Based on previous research, stable lipid complexes with uniform particle sizes were constructed using cytidinyl lipid DNCA/cationic lipid CLD (Mix) supplemented with DSPE-PEG (siIGF1R/Mix/PEG). The complexes were formed through hydrogen-bonding, π-π stacking, and electrostatic interactions. The siIGF1R/Mix/PEG complex entered the cytoplasm and nucleus of HCC cells, reduced IGF1R mRNA and pre-mRNA levels by over 95% and 50% respectively, further arrested the cell cycle in the S phase, and promoted cell apoptosis. Importantly, siIGF1R/Mix/PEG (0.8 mg/kg, i.v.) selectively accumulated in the tumor, significantly inhibiting tumor growth by 91.31% compared to the naked siRNA group, with slower release and a more prolonged effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularReceptor, IGF Type 1RNA, Small InterferingLiver NeoplasmsLipidsHumansApoptosisCell Line, TumorAnimalsMiceCell ProliferationMice, NudeXenograft Model Antitumor AssaysHep G2 CellsCationsRNA, MessengerMice, Inbred BALB CInsulin-Like Peptides

Stichwörter der Autor:innen

Cationic lipidCytidinyl lipidHepatocellular carcinomaInsulin-like growth factor 1 receptorModified siRNA

Substanzen

Receptor, IGF Type 1RNA, Small InterferingLipidsIGF1R protein, humanCationsRNA, MessengerInsulin-Like Peptides

Autor:innen und Institutionen

  • State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
  • School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
  • Genable (Beijing) Biotechnology Co. Ltd, #38 Yongda Road, Beijing 102609, China.

ORCID-Profile: Yufei Pan, Zhenjun Yang

Förderung

  • Natural Science Foundation of Beijing Municipality
  • Beijing Daxing Biomedical Industry Base

Zitieren

APA

Pu, Y., Wang, Q., Pan, Y., Wang, X., Guan, Z., Zhu, Y., & Yang, Z. (2025). Cytidinyl/Cationic Lipid Encapsulating Insulin-Like Growth Factor 1 Receptor siRNA for Hepatocellular Carcinoma Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01318

Vancouver

Pu Y, Wang Q, Pan Y, Wang X, Guan Z, Zhu Y, et al. Cytidinyl/Cationic Lipid Encapsulating Insulin-Like Growth Factor 1 Receptor siRNA for Hepatocellular Carcinoma Therapy. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01318

BibTeX
@article{Pu2025,
  author = {Pu, Yang and Wang, Quanxin and Pan, Yufei and Wang, Xixian and Guan, Zhu and Zhu, Yuejie and Yang, Zhenjun},
  title = {Cytidinyl/Cationic Lipid Encapsulating Insulin-Like Growth Factor 1 Receptor siRNA for Hepatocellular Carcinoma Therapy},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c01318}
}
Kostenlos starten →